Charing Cross Special Edition
Global vascular community to strive for consensus at CX
The Charing Cross Symposium (CX; 21–24 April, London, UK) is the longest-running vascular and endovascular global symposium, and an important source of Education, Innovation, and Evidence as the vascular field in 2020 seeks clarity and truth.
F
our CX Special Sessions have been introduced to the programme to focus on those topics that are seen as most central to the vascular community and warrant highlighting.
Paclitaxel-coated device update
On Tuesday 21 April, the first CX Special Session will address the latest hypotheses and controversies in the debate
surrounding the use of paclitaxel-coated devices in the lower limb. New meta-analyses into the use of paclitaxel-coated devices in chronic limb-threatening ischaemia patients will be reported. The purpose will be to summarise what is new and learned in paclitaxel usage. CX 2020 will distil the science from the hype, and tease out the evidence from the opinion—all the while keeping
| March 2020
patients, and their physicians, front and centre. This Special Session will include input from the world-class CX Faculty, the regulatory bodies, and from an expert audience.
Durability of EVAR, sac diameter and NICE guidelines
The second CX Special Session on Wednesday 22 April will focus on the durability of endovascular aneurysm repair (EVAR), the importance of sac diameter, and the draft National Institute for Health and Care Excellence (NICE) aortic aneurysm guidelines. The draft guidelines, published in May 2018, recommended that UK healthcare professionals favour open repair for aneurysms over endovascular repair. While the final guidelines remain unpublished at the time of writing, they could—if implemented—change vascular practice significantly. Elective aortic EVAR would not be funded, as it is said not to be cost-effective in secondary and tertiary care. New approaches will be described. In addition, collaboration will be a key theme, with a number of experts in the
field detailing efforts to seek consensus amid uncertainty.
Type B aortic dissections consensus
Another aortic Special Session, scheduled to take place on Thursday 23 April, will be devoted to reaching consensus in the field of type B aortic dissection. One CX Debate will address whether or not early intervention is less risky in the modern endovascular era, while another will consider the motion that many uncomplicated type B dissections do not need repair. Furthermore, a number of experts will discuss updates in treatment.
EndoAVF virtual reality edited cases
The fourth CX Special Session at this year’s meeting will take place on Wednesday 22 April during the Vascular Access Masterclass. The session will cover virtual reality edited cases with endovascular arteriovenous fistula (endo AVF) technologies. Delegates will have the opportunity to immerse themselves in the experience with the use of highresolution goggles.